id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-269659-a1gf76bu	Hong, W.	Celebrex adjuvant therapy on COVID-19: An experimental study	2020-05-11		.txt	text/plain	3095	182	56	Celebrex significantly reduced the PGE2 levels and promoted recovery of ordinary or severe COVID-19. Our data showed that the PGE 2 levels in COVID-19 patients, who were hospitalized within two days, were significantly higher than the ones of healthy individuals (170±40 ng/ml vs 18.8±3.8 ng/ml, p<0.01) (Figure 1 ). Since the PGE 2 was mainly generated by COX-2, then a COX-2 specific inhibitor (Celebrex) was used to treat COVID-19 patients based on the routine treatment. Our results indicated that Celebrex treatment with a conventional dose (0.2 g, twice a day) might effectively promote the recovery of ordinary and severe cases of COVID-19. Moreover, there were two patients (experimental case E3 and E5), who were hospitalized and received routine treatment for 12 and 15 days respectively, progressed from ordinary to severe illness. After taken Celebrex based on routine treatment, their PGE 2 levels were controlled and the pneumonia were gradually improved ( Figure 4 ).	./cache/cord-269659-a1gf76bu.txt	./txt/cord-269659-a1gf76bu.txt